

Supplementary Table S1. Prescription review status from March to June 2023


Characteristics	March			April			May			June			Between different months	
	<i>n</i> (%)	χ^2/Z	<i>P</i>	<i>n</i> (%)	χ^2/Z	<i>P</i>	<i>n</i> (%)	χ^2/Z	<i>P</i>	<i>n</i> (%)	χ^2/Z	<i>P</i>	χ^2/Z	<i>P</i>
Prescription Review Status														
Total														
Initial Prescriptions	66,991			55,027			60,620			55,875				
Final Prescriptions	66,390			54,618			60,115			53,262				
Irrational Prescriptions		382.013	**		174.431	**		221.930	**		84.823	**		
Initial Irrational Prescriptions	18,527 (27.7)			13,120 (23.8)			15,336 (25.3)			13,441 (24.1)			303.951	**
Final Irrational Prescriptions	15,270 (23.0)			11,212 (20.5)			13,023 (21.7)			11,564 (21.7)			108.882	**
Risk Level [#]		832.985	*** ^a		586.431	*** ^a		741.078	*** ^a		481.105	*** ^a		
Initial													226.934	*** ^a
High Risk	2,519 (13.6)			1,824 (13.9)			2,030 (13.2)			1,714 (12.8)				
Moderate Risk	4,132 (22.3)			1,936 (14.8)			2,918 (19.0)			2,024 (15.1)				
Low Risk	11,876 (64.1)			9,360 (71.3)			10,388 (67.7)			9,703 (72.2)				
Final													214.6	*** ^a
High Risk	307 (2.0)			214 (1.9)			178 (1.4)			168 (1.5)				
Moderate Risk	3,312 (21.7)			1,716 (15.3)			2,425 (18.6)			1,896 (16.4)				
Low Risk	11,651 (76.3)			9,282 (82.8)			10,420 (80.0)			9,500 (82.2)				
Cost situation														
Total														
Initial Prescription Amount (CNY)	2,333,626.2			1,669,220.0			1,987,196.5			1,796,740.6				
Final Prescription Amount (CNY)	1,818,822.1			1,470,406.2			1,707,496.6			1,575,288.1				
Saving														
Cost Savings on Medication (CNY)	514,804.1			198,813.8			279,699.9			221,452.6				
Average Medication Cost Saved per Initial Prescription (CNY / CASE)	34.8			30.3			32.8			32.2				
Average Medication Cost Saved per Final Prescription (CNY / CASE)	27.4			26.9			28.4			29.6				
Average Cost Savings per Prescription (CNY / CASE)	7.4			3.4			4.4			2.6				

Note. ** $P < 0.001$. ^aWilcoxon rank-sum test. [#]Risk Level: Low Risk: inappropriate drug selection, incorrect solvent selection judgment, lack of solvent judgment, incorrect solvent dosage judgment, inappropriate dosing frequency, and excessive treatment duration. Moderate Risk: Harmful drug interactions, repeated medication less than twice; off-label use: antibiotics for non-infectious diagnoses or complications of infectious diseases. High Risk: Absolute contraindications, repeated medication more than twice, off-label use: antibiotics for non-infectious diseases, antibiotics for nonbacterial infectious diagnoses.

Supplementary Table S2. Cost components of prescription review

Cost	CNY / CASE	%
Total	2.40	-
Fixed Cost	2.29	95.2
Equipment Depreciation	0.97	40.2
Intelligent Prescription Review System	0.880	36.6
Front-end Server	0.036	1.5
Application Server	0.003	0.1
Bastion Host	0.015	0.6
Operating System Anti-virus Software	0.010	0.4
Third-Party Interface Fee	0.022	0.9
Equipment Maintenance	1.32	54.9
Maintenance and Upgrade	1.32	54.9
Variable Cost	0.116	4.8
Labor Costs	0.116	4.8
Associate Chief Physician / Chief Physician	0.007	0.3
Attending Physician	0.026	1.1
Physician	0.052	2.2
Medical Assistant	0.031	1.3

Note. Rounded to the nearest decimal place.

**Supplementary Figure S1.** The AIAPRS prescription review process.